In human cord blood-derived endothelial progenitor cells, 10 μM FMK pretreatment reduced SDF-1-induced RelA phosphorylation and CXCR4 protein expression without reducing ERK phosphorylation. This was a cellular pathway-probe experiment; the paper’s kidney-protection findings used other interventions. [3]
In primary rat vascular smooth muscle cells, FMK reduced PDGF-BB-induced proliferation-associated readouts, including cell counts, BrdU incorporation and Ki-67. The accompanying Annexin V/PI experiment did not show apoptosis induction at 10 μM FMK under the tested conditions. [4]
RSK2 C-terminal domain inhibition and selectivity-filter controls
Biochemical assay · Activated recombinant WT, C436V and T493M RSK2 C-terminal domains [1]
FMK inhibited WT RSK2 CTD much more strongly than either selectivity-filter mutant. A non-electrophilic scaffold was weaker against WT; labeling by the separate biotin-FMK probe supported a covalent targeting mechanism.
Literature-Reported Treatment Conditions
- Treatment concentration
- Concentration-response FMK; exact range not specified in Table 1. Separate labeling control: 1 μM biotin-FMK.
- Exposure duration
- 30-min pretreatment for inhibition; 1 h for biotin-FMK labeling.
- Method
- Kinase activity assay and mechanistic labeling control.
- Reported limits
- Main text does not define n or the ± term in Table 1. SI PDF was not retrieved; inhibition reaction duration and vehicle remain unavailable.
Methods and source locations
Compound reported in the paper: FMK; Compound label in the paper: fmk
Applies to the reported FMK research material and model; does not validate an Adooq lot or establish clinical efficacy.
Table 1 and caption; biochemical RSK2 Results; Fig. 1B and Fig. 2A/caption
Wild-type RSK2 C-terminal domain kinase activity: 1 nM activated RSK2 CTD, 0.1 mM ATP, 0.1 mM CTD-tide; 30-min inhibitor pretreatment. — Table 1, fmk row, WT column and caption
C436V RSK2 CTD kinase activity: Same Table 1 assay; mutant activities reported similar to WT. — Table 1, fmk row, C436V column
T493M RSK2 CTD kinase activity: Same Table 1 assay. — Table 1, fmk row, T493M column
WT RSK2 CTD inhibition by non-electrophilic scaffold control: Comparator scaffold, not FMK; same Table 1 assay. — Table 1, scaffold row, WT column
Covalent-labeling control using biotin-FMK, a derivative of FMK: 1 μM biotin-FMK for 1 h; denaturing electrophoresis and streptavidin-HRP with His6 protein detection controls. This is not a potency measurement of parent FMK. — Fig. 2A image/caption and preceding Results paragraph
Endogenous RSK2 activation in EGF-stimulated COS-7 cells
Cell-based study · Serum-starved COS-7 cells stimulated with EGF [1]
FMK reduced endogenous RSK2 Ser386 autophosphorylation, while 10 μM FMK did not suppress the measured EGF-induced ERK1/2 phosphorylation signal.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0, 0.3, 1, 3 and 10 μM FMK in Fig. 3A; 10 μM for ERK control.
- Exposure duration
- 20 h serum deprivation; EGF stimulation for 10 min. FMK pretreatment duration unavailable in retrieved main text.
- Method
- EGF 1 ng/mL; RSK2 immunoprecipitation and immunoblot; phospho/total ERK immunoblot.
- Co-treatment
- EGF stimulation; no second inhibitor in the selected comparison.
- Reported limits
- FMK pretreatment duration/vehicle not stated in retrieved main caption; linked SI was not retrieved. No replicate count given for these blots.
Methods and source locations
Compound reported in the paper: FMK; Compound label in the paper: fmk
Applies to the reported FMK research material and model; does not validate an Adooq lot or establish clinical efficacy.
Fig. 3A–B images/captions and endogenous RSK2 Results
EGF-induced endogenous RSK2 Ser386 phosphorylation: Author-reported cellular EC50; not read from a curve. Total RSK2 loading/control blot. — Fig. 3A image/caption and preceding endogenous RSK2 Results paragraph
EGF-stimulated ERK1/2 phosphorylation: Phospho-ERK and total ERK blots; EGF-only and unstimulated controls. — Fig. 3B image/caption and corresponding Results paragraph
Kinase profiling defines off-target and activation-state limits
Biochemical assay · Purified kinase activity panel, including activated RSK1/RSK2 and non-RSK kinases [2]
The panel found submicromolar inhibition of Src, Lck, S6K1, Yes and Eph-A2. Activated RSK1/2 largely retained catalytic activity, consistent with an inhibitor of CTD-dependent activation rather than direct inhibition of active N-terminal kinase activity.
Literature-Reported Treatment Conditions
- Treatment concentration
- 3 μM FMK for Table 3 panel; ten inhibitor concentrations for Table 5 IC50 determinations.
- Exposure duration
- 30-min activity assays at 21 °C.
- Method
- Radiometric kinase assays; ATP varied by enzyme as specified per measurement.
- Reported limits
- Vehicle and Table 5 replicate/dispersion details not specified in the selected table caption. Table 3 ± terms are retained without assigning an uncertainty type.
Methods and source locations
Compound reported in the paper: FMK; Compound label in the paper: FMK
Applies to the reported FMK research material and model; does not validate an Adooq lot or establish clinical efficacy.
Materials and methods: Materials, Protein kinase assays; Tables 3 and 5; RSK inhibitor discussion
Inhibition of Src kinase activity: Ten inhibitor concentrations; 50 μM ATP; 30-min activity assay at 21 °C. — Table 5, FMK/Src row
Inhibition of Lck kinase activity: Ten inhibitor concentrations; 50 μM ATP; 30-min activity assay at 21 °C. — Table 5, FMK/Lck row
Inhibition of S6K1 kinase activity: Ten inhibitor concentrations; 20 μM ATP; 30-min activity assay at 21 °C. — Table 5, FMK/S6K1 row
Inhibition of Yes kinase activity: Ten inhibitor concentrations; 20 μM ATP; 30-min activity assay at 21 °C. — Table 5, FMK/Yes row
Inhibition of Eph-A2 kinase activity: Ten inhibitor concentrations; 50 μM ATP; 30-min activity assay at 21 °C. — Table 5, FMK/Eph-A2 row
Activity of already activated RSK1 in FMK: 3 μM FMK, 50 μM ATP; inhibitor-omitted control. Duplicate determinations; experiment repeated two or three times with similar results. Caption does not define ± term. — Table 3, RSK1 row, FMK (3 μM) column and caption
Activity of already activated RSK2 in FMK: 3 μM FMK, 50 μM ATP; inhibitor-omitted control. Duplicate determinations; experiment repeated two or three times with similar results. Caption does not define ± term. — Table 3, RSK2 row, FMK (3 μM) column and caption
SDF-1 signaling in human endothelial progenitor cells
Cell-based study · Human umbilical cord blood-derived late endothelial progenitor cells [3]
FMK pretreatment decreased SDF-1-induced RelA phosphorylation and CXCR4 protein expression without reducing ERK phosphorylation in the selected immunoblots.
Literature-Reported Treatment Conditions
- Treatment concentration
- 10 μM FMK.
- Exposure duration
- FMK pretreatment 30 min; SDF-1 stimulation 10 min for signaling or 6 h for CXCR4.
- Method
- SDF-1 100 ng/mL; immunoblots with total-protein and β-actin controls.
- Vehicle
- DMSO negative control.
- Co-treatment
- SDF-1 challenge; PD98059 and Helenalin tested separately as pathway comparators.
- Reported limits
- General methods state western blots were performed at least in triplicate; independent donor n is not specified for Fig. 3B. No catalog number or lot specified.
Methods and source locations
Compound reported in the paper: FMK; Compound label in the paper: FMK
Applies to the reported FMK research material and model; does not validate an Adooq lot or establish clinical efficacy.
Fig. 3B image/caption; Results: SDF-1 induces CXCR4 expression via the non-canonical NF-κB signaling pathway in EPCs; Methods: Isolation of EPCs and cell culture; Immunoprecipitation and western blot analysis
SDF-1-induced RelA phosphorylation: Phospho/total RelA immunoblot after 10 min SDF-1. — Fig. 3B upper immunoblots and Results paragraph preceding Fig. 3
SDF-1-induced CXCR4 protein expression: CXCR4 immunoblot after 6 h SDF-1; β-actin loading control. — Fig. 3B lower immunoblots and corresponding Results
SDF-1-induced ERK phosphorylation: Phospho/total ERK control after 10 min SDF-1. — Fig. 3B upper immunoblots and corresponding Results
PDGF-BB-induced proliferation in primary rat vascular smooth muscle cells
Cell-based study · Primary rat VSMCs, passages 4–7, under serum-free experimental conditions [4]
FMK lowered PDGF-BB-induced MTT signal, cell accumulation, BrdU incorporation and Ki-67 readouts. The Annexin V/PI control did not show induction of apoptosis at 10 μM in the tested setting.
Literature-Reported Treatment Conditions
- Treatment concentration
- 1, 2, 5, 10 μM FMK for MTT; 2 and 5 μM for cell counts/BrdU/Ki-67; 10 μM for apoptosis control.
- Exposure duration
- 1 h pretreatment then 24 h PDGF-BB in Fig. 1. BrdU methods additionally describe a 24 h labeling incubation after the initial 24 h PDGF-BB exposure.
- Method
- PDGF-BB 2 ng/mL; MTT, cell counting, BrdU, Ki-67 and Annexin V/PI as complementary proliferation/cell-death readouts.
- Co-treatment
- PDGF-BB stimulus; BI-D1870 is a separate comparator, not a co-treatment.
- Reported limits
- Vehicle composition not specified. BrdU timing differs in granularity between methods and caption; not collapsed to a single total exposure. Caption describes data representative of three independent experiments.
Methods and source locations
Compound reported in the paper: FMK; Compound label in the paper: FMK
Applies to the reported FMK research material and model; does not validate an Adooq lot or establish clinical efficacy.
Results 2.1; Fig. 1B,D–H images/caption; Methods 4.1–4.2, 4.6–4.7, 4.9–4.11
PDGF-BB-induced proliferation-associated readouts: MTT dose series plus cell counts, BrdU incorporation and Ki-67 staining/blots; unstimulated and PDGF-BB-only controls. — Fig. 1B,D,F–H images/caption; Results 2.1; Methods 4.6–4.7
Apoptosis at 10 μM FMK: Annexin V-FITC/PI flow cytometry; this endpoint does not establish general safety or absence of all cytotoxicity. — Fig. 1E image/caption; Results 2.1; Methods 4.11